Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Association of Increased Lung Resistance Protein Expression with Acquired Etoposide Resistance in Human H460 Lung Cancer Cell Lines

  • Lee, Eun-Myong (Department of Bioscience and Biotechnology, Sejong University) ;
  • Lim, Soo-Jeong (Department of Bioscience and Biotechnology, Sejong University)
  • Published : 2006.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Chemoresistance remains the major obstacle to successful therapy of cancer. In order to understand the mechanism of multidrug resistance (MDR) that is frequently observed in lung cancer patients, here we studied the contribution of MDR-related proteins by establishing lung cancer cell lines with acquired resistance against etoposide. We found that human H460 lung cancer cells responded to etoposide more sensitively than A549 cells. Among MDR-related proteins, the expression of p-glycoprotein (Pgp) and lung resistance protein (LRP) were much higher in A549 cells compared with that in H460 cells. When we established H460-R1 and -R2 cell lines by progressive exposure of H460 cells to increasing doses of etoposide, the response against etopbside as well as doxorubicin was greatly reduced in R1 and R2 cells, suggesting MDR induction. Induction of MDR was not accompanied by a decrease in the intracellular accumulation of etoposide and the expression of MDR-related proteins that function as drug efflux pumps such as Pgp and MRP1 was not changed. We found that the acquired resistance paralleled an increased expression of LRP in H460 cells. Taken together, our data suggest the implicative role of LRP in mediating MDR in lung cancer.

Keywords

References

  1. Aita, P., Robieux, I., Sorio, R., Tumolo, S., Corona, G., Cannizzaro, R., Colussi, A. M., Boiocchi, M., and Toffoli, G., Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother. Pharmacol., 43, 287- 294 (1999) https://doi.org/10.1007/s002800050897
  2. Berger, W., Elbling, L., and Micksche, M., Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int. J. Cancer, 88, 293-300 (2000) https://doi.org/10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S
  3. Berger, W., Spiegl-Kreinecker, S., Buchroithner, J., Elbling, L., Pirker, C., Fischer, J., and Micksche, M., Overexpression of the human major vault protein in astrocytic brain tumor cells. Int. J. Cancer, 94, 377-382 (2001) https://doi.org/10.1002/ijc.1486
  4. Borst, P., Evers, R., Kool, M., and Wijnholds, J., A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 92, 1295-1302 (2000) https://doi.org/10.1093/jnci/92.16.1295
  5. Dingemans, A. M., van Ark-Otte, J., van der Valk, P., Apolinario, R. M., Scheper, R. J., Postmus, P. E., and Giaccone, G., Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann. Oncol., 7, 625-630 (1996) https://doi.org/10.1093/oxfordjournals.annonc.a010681
  6. Filipits, M., Pohl, G., Stranzl, T., Suchomel, R. W., Scheper, R. J., Jager, U., Geissler, K., Lechner, K., and Pirker, R., Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood, 91, 1508-1513 (1998)
  7. Hu, Y., Stephen, A. G., Cao, J., Tanzer, L. R., Slapak, C. A., Harrison, S. D., Devanarayan, V., Dantzig, A. H., Starling, J. J., Rome, L. H., and Moore, R. E., A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells. In.t J. Cancer, 97, 149-156 (2002) https://doi.org/10.1002/ijc.1590
  8. Ihde, D. C. and Minna, J. D., Non-small cell lung cancer. Part II: Treatment. Curr Probl Cancer, 15, 105-154 (1991)
  9. Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Shoemaker, R. H., Rome, L. H., and Scheper, R. J., Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology, 19, 191-197 (1996) https://doi.org/10.1007/BF00744212
  10. Kang, Y. H., Lee, E., Youk, H. J., Kim, S. H., Lee, H. J., Park, Y. G., and Lim, S. J., Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1- expressing glioblastoma cells. Cancer Lett., 217, 181-190 (2005) https://doi.org/10.1016/j.canlet.2004.07.016
  11. Kitazono, M., Okumura, H., Ikeda, R., Sumizawa, T., Furukawa, T., Nagayama, S., Seto, K., Aikou, T., and Akiyama, S., Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int. J. Cancer, 91, 126-131 (2001) https://doi.org/10.1002/1097-0215(20010101)91:1<126::AID-IJC1018>3.0.CO;2-8
  12. Kitazono, M., Sumizawa, T., Takebayashi, Y., Chen, Z. S., Furukawa, T., Nagayama, S., Tani, A., Takao, S., Aikou, T., and Akiyama, S., Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW- 620 cells. J. Natl. Cancer Inst., 91, 1647-1653 (1999) https://doi.org/10.1093/jnci/91.19.1647
  13. Lee, E. M., Hong, S. H., Lee, Y. J., Kang, Y. H., Choi, K. C., Choi, S. H., Kim, I. H., and Lim, S. J., Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor. J. Cancer Res. Clin. Oncol., 132, 223-233 (2003) https://doi.org/10.1007/s00432-005-0063-7
  14. Meschini, S., Marra, M., Calcabrini, A., Monti, E., Gariboldi, M., Dolfini, E., and Arancia, G., Role of the lung resistancerelated protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol. In Vitro, 16, 389-398 (2002) https://doi.org/10.1016/S0887-2333(02)00035-8
  15. Mossink, M. H., van Zon, A., Scheper, R. J., Sonneveld, P., and Wiemer, E. A., Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene, 22, 7458-7467 (2003) https://doi.org/10.1038/sj.onc.1206947
  16. Ohsawa, M., Ikura, Y., Fukushima, H., Shirai, N., Sugama, Y., Suekane, T., Hirayama, M., Hino, M., and Ueda, M., Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology, 68, 422-431 (2005) https://doi.org/10.1159/000086984
  17. Rybarova, S., Hajdukova, M., Hodorova, I., Kocisova, M., Boor, A., Brabencova, E., Kasan, P., Biros, E., Mojzis, J., and Mirossay, L., Expression of the multidrug resistanceassociated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer. Neoplasma, 51, 169- 174 (2004)
  18. Sawada, M., Nakashima, S., Kiyono, T., Nakagawa, M., Yamada, J., Yamakawa, H., Banno, Y., Shinoda, J., Nishimura, Y., Nozawa, Y., and Sakai, N., p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells. Oncogene, 20, 1368-1378 (2001) https://doi.org/10.1038/sj.onc.1204207
  19. Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Kaaijk, P., Dalton, W. S., van Heijningen, T. H., van Kalken, C. K., Slovak, M. L., de Vries, E. G., and van der Valk, P., Overexpression of a M(r) 110,000 vesicular protein in non-Pglycoprotein- mediated multidrug resistance. Cancer Res., 53, 1475-1479 (1993)
  20. Sugimoto, Y., Tsukahara, S., Ishikawa, E., and Mitsuhashi, J., Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci., 96, 457-465 (2005) https://doi.org/10.1111/j.1349-7006.2005.00081.x
  21. Troyano, A., Fernandez, C., Sancho, P., de Blas, E., and Aller, P., Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J. Biol. Chem., 276, 47107- 47115 (2001) https://doi.org/10.1074/jbc.M104516200
  22. Young, L. C., Campling, B. G., Cole, S. P., Deeley, R. G., and Gerlach, J. H., Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res., 7, 1798-1804 (2001)
  23. Zhang, Y., Gupta, A., Wang, H., Zhou, L., Vethanayagam, R. R., Unadkat, J. D., and Mao, Q., BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers. Pharm. Res., 22, 2023-2034 (2005) https://doi.org/10.1007/s11095-005-8384-4